Dorzagliatin

多格列艾汀

Report date: 2026/05/02 20:00:18
NMEFirst In Class

Base Information

Drug NameDorzagliatin
Drug Alias Name多扎格列艾汀SinogliatinDorzagliatin controlled release华堂宁HMS-5552 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucokinase activators
TargetsGlucokinase
Therapy Area/IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Diabetes Mellitus +[7] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2022/10/08
Country/TerritoryBulgariaUnited StatesSlovakia +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHua Medicine Technology (Hong Kong) LtdChinese University Of Hong Kong (Cuhk)University Of Pennsylvania +[5] 
Inactive CompaniesF. Hoffmann-La Roche LtdBayer AGHua Medicine Ltd +[4] 
Active IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Diabetes Mellitus +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeA10B
Related LinksDrugBankKEGG